Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Teprotumumab (Tepezza)

decorative image of the issue cover

Published July 22, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Teprotumumab (Tepezza), 500 mg lyophilized powder in a single-dose vial for reconstitution and IV use.
  • Indication: In adults for the treatment of moderate to severe active Thyroid Eye Disease (TED).